Emerging techniques for determining the tissue of origin in patients with unknown primary carcinoma.
New molecular tests to assign a putative tissue of origin in patients with carcinoma of unknown primary (CUP) have recently become commercially available. This editorial addresses this new technology in terms of our current understanding of CUP, and how these tests may affect its management.